JP2011522864A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522864A5
JP2011522864A5 JP2011512988A JP2011512988A JP2011522864A5 JP 2011522864 A5 JP2011522864 A5 JP 2011522864A5 JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011522864 A5 JP2011522864 A5 JP 2011522864A5
Authority
JP
Japan
Prior art keywords
use according
seq
medicament
amino acid
cac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011512988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522864A (ja
JP5481473B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/057263 external-priority patent/WO2009150214A2/en
Publication of JP2011522864A publication Critical patent/JP2011522864A/ja
Publication of JP2011522864A5 publication Critical patent/JP2011522864A5/ja
Application granted granted Critical
Publication of JP5481473B2 publication Critical patent/JP5481473B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011512988A 2008-06-13 2009-06-12 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体 Expired - Fee Related JP5481473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6116308P 2008-06-13 2008-06-13
US61/061,163 2008-06-13
PCT/EP2009/057263 WO2009150214A2 (en) 2008-06-13 2009-06-12 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease

Publications (3)

Publication Number Publication Date
JP2011522864A JP2011522864A (ja) 2011-08-04
JP2011522864A5 true JP2011522864A5 (enExample) 2012-07-05
JP5481473B2 JP5481473B2 (ja) 2014-04-23

Family

ID=41078180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512988A Expired - Fee Related JP5481473B2 (ja) 2008-06-13 2009-06-12 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体

Country Status (8)

Country Link
US (2) US8476408B2 (enExample)
EP (1) EP2310041B1 (enExample)
JP (1) JP5481473B2 (enExample)
CN (1) CN102065883A (enExample)
AU (1) AU2009256558B2 (enExample)
CA (1) CA2723270C (enExample)
MX (1) MX2010013677A (enExample)
WO (1) WO2009150214A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9651708B2 (en) * 2011-04-21 2017-05-16 Baker Hughes Incorporated Method of mapping reservoir fluid movement using gravity sensors
US20140336109A1 (en) * 2011-12-15 2014-11-13 Alize Pharma Sas Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US20160151458A1 (en) * 2013-06-21 2016-06-02 Alize Pharma Sas Use Of Unacylated Ghrelin, Fragments And Analogs Thereof As Antioxidant
EP3137098A4 (en) * 2014-04-29 2017-11-01 Mayo Foundation for Medical Education and Research Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
WO2018053216A1 (en) 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5747296A (en) * 1992-05-11 1998-05-05 Corvas International, Inc. Method of detecting neutophil inhibitory factor mimics
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5695761A (en) * 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
DE69533704D1 (de) * 1994-03-09 2004-12-02 Cortech Inc Bradykinin-antagonist peptide mit n-substituierten glycinen
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
US6627729B1 (en) 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
AU6515499A (en) * 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
EP1286697A2 (en) 2000-05-17 2003-03-05 Eli Lilly And Company Method for selectively inhibiting ghrelin action
EP1353683A4 (en) 2000-05-30 2004-05-12 Merck & Co Inc ANALOGS BY GHRELIN
US6872548B2 (en) 2001-01-31 2005-03-29 Human Genome Sciences, Inc. Scaffolded fusion polypeptides and compositions and methods for making the same
WO2002060472A1 (fr) 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedes pour des etats d'hyponutrition
ATE552031T1 (de) 2001-12-18 2012-04-15 Alize Pharma Sas Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
JP5000848B2 (ja) 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
JP2006527738A (ja) * 2003-06-18 2006-12-07 ディレボ・ビオテク・アーゲー 新規生物学的実体およびその薬学的または診断的使用
US7517269B2 (en) 2003-08-12 2009-04-14 Parvia Corp. Building element for constructing a modular substructure
US7825090B2 (en) 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006019577A1 (en) * 2004-07-14 2006-02-23 Eli Lilly And Company Anti-ghrelin antibodies
WO2006045319A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
JP2008520204A (ja) * 2004-11-15 2008-06-19 イーライ リリー アンド カンパニー 非アシル化グレリン抗体及びその治療への使用
JP5147827B2 (ja) 2006-03-28 2013-02-20 リアット・ミンツ 高コレステロール血症および／または高コレステロールおよび／または高コレステロール関連疾患および／または脂血症および／または脂血症関連疾患および／または冠動脈疾患および／または体重管理および／または糖尿病および／または高血糖の治療のためのグレリンスプライス変種の使用
MX2009012969A (es) 2007-05-31 2010-04-27 Alize Pharma Sas Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos.
EP2067481A1 (en) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin

Similar Documents

Publication Publication Date Title
JP2011522864A5 (enExample)
JP2010031018A5 (enExample)
JP2014501762A5 (enExample)
EA201691347A3 (ru) Терапия глатирамером ацетатом с низкой кратностью
JP2013515009A5 (enExample)
RU2020111236A (ru) Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
JP2016516016A5 (enExample)
JP2011105728A5 (enExample)
JP2018052983A5 (enExample)
JP2011225596A5 (enExample)
JP2010532761A5 (enExample)
JP2011528333A5 (enExample)
JP2020062028A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2013510169A5 (enExample)
JP2014532722A5 (enExample)
JP2016512205A5 (enExample)
JP2014506579A5 (enExample)
JP2009519949A5 (enExample)
JP2017509690A5 (enExample)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
WO2009150214A3 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
WO2021199006A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP2014500244A5 (enExample)
WO2007029041A2 (en) Interferon lambda therapy for treatment of respiratory diseases